Amerika Serikat - Inggris - NLM (National Library of Medicine)

major pharmaceuticals - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules, usp are indicated in adults for the treatment of: dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing, and throat tightness [see adverse reactions (6.2)] . risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations] . cannabinoids have been found in the umbilical cord blood from pregnant women who smoke cannabis. in animal reproduction studies, no teratogenicity was reported in mice administered dronabinol at up to 30 times the mrhd (maximum recommended human dose) and up t

Amerika Serikat - Inggris - NLM (National Library of Medicine)

camber pharmaceuticals inc - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules is indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids).  - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules is contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)] . risk summary dronabinol, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations] . cannabinoids have been found

Amerika Serikat - Inggris - NLM (National Library of Medicine)

avkare - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules is indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids).  - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules is contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)] . risk summary dronabinol, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations] . cannabinoids have been found

Amerika Serikat - Inggris - NLM (National Library of Medicine)

major pharmaceuticals - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules are indicated in adults for the treatment of: dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)] . dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations] . cannabinoids have been found in the umbilical cord blood from pregnant women who smoke cannabis. in animal reproduction studies, no teratogenicity was reported in mice administered dronabinol at up to 30 times the mrhd (maximum recommended human dose) and up to 5 times the mrhd

Amerika Serikat - Inggris - NLM (National Library of Medicine)

major pharmaceuticals - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules are indicated in adults for the treatment of: dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)]. risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations]. cannabinoids have been found in the umbilical cord blood from pregnant women who smoke cannabis. in animal reproduction studies, no teratogenicity was reported in mice administered dronabinol at up to 30 times the mrhd (maximum recommended human dose) and up to 5 time

Amerika Serikat - Inggris - NLM (National Library of Medicine)

bryant ranch prepack - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)]. risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations]. cannabinoids have be

Amerika Serikat - Inggris - NLM (National Library of Medicine)

bryant ranch prepack - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)]. risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations]. cannabinoids have be

Amerika Serikat - Inggris - NLM (National Library of Medicine)

lannett company, inc. - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids).  - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules, are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)] . risk summary dronabinol, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes (see clinical considerations). cannabinoids have been fou

Amerika Serikat - Inggris - NLM (National Library of Medicine)

bryant ranch prepack - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)]. risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations]. cannabinoids have be

Amerika Serikat - Inggris - NLM (National Library of Medicine)

bryant ranch prepack - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)]. risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations]. cannabinoids have be